Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 8/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10492749 | 0.83 | KMT2A (0.58) | MITFKMT2AHIF1AUSP2MAPK9 | |
| SCHEMBL10492730 | 0.83 | KMT2A (0.58) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL153098 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL365913 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL1649685 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL15375600 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL153100 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL15068213 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| Nifuratel SCHEMBL16675657 | 0.82 | HIF1A (0.68) | MITFKMT2AHIF1AUSP2MAPK9 | |
| SCHEMBL29772890 | 0.81 | KMT2A (0.78) | MITFKMT2AHIF1AUSP2MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | Bio Logic Crop Science S.L. (ES) | 2025-01-16 | — | — | US | disclosed |
| EP-4427745-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science, S.L. (ES) | 2024-09-11 | — | — | EP | disclosed |
| US-11766364-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023079206-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION METHOD THEREOF | Bio Logic Crop Science S.L. (ES) | 2023-05-11 | — | — | WO | disclosed |
| US-11452641-B2 | Wound closure systems for reducing surgical site infections comprising incision drapes filled with releasable antimicrobial agents | ETHICON, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220296422-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220296423-A1 | Wound Closure Systems for Reducing Surgical Site Infections Comprising Incision Drapes Filled with Releasable Antimicrobial Agents | ETHICON, INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | MITF 1985/4885KMT2A 4460/4885HIF1A 465/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | MITF 1938/4885KMT2A 4761/4885HIF1A 180/4885 |
| US-20250017879-A1 | COMPOSITION WITH VIRUCIDAL ACTIVITY, USE AND APPLICATION THEREOF | SARS1, ACE2, PHOSPHO1 | MITF 714/4885KMT2A 1223/4885HIF1A 2064/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | MITF 1528/4885KMT2A 4411/4885HIF1A 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.